# BridgeBio Pharma, Inc. (BBIO) insider trading

> In the 12 months to Nov 19, 2026, 8 BBIO insiders reported open-market sales of $93.5M across 33 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/bbio/insider-trading
Latest filing: 2026-11-18 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $93.5M | 33 filings · 8 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 32 of 33 | $87.2M of $93.5M sold (93%) |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Neil Kumar | Chief Executive Officer | $52.2M | — | 13 | 100% of sales | 2026-09-21 |
| Jennifer E. Cook | Director | $21.9M | — | 3 | 100% of sales | 2026-07-13 |
| Andrew Lo | Director | $6.3M | — | 1 | — | 2025-11-19 |
| Andrea Ellis | Director | $5.7M | — | 2 | 100% of sales | 2026-07-13 |
| Hannah Valantine | Director | $2.7M | — | 3 | 100% of sales | 2026-06-24 |
| Randal W. Scott | Director | $2.1M | — | 3 | 100% of sales | 2026-05-19 |
| Thomas Trimarchi | President and CFO | $1.9M | — | 2 | 100% of sales | 2026-05-19 |
| Maricel Apuli | Chief Accounting Officer | $767.4K | — | 6 | 100% of sales | 2026-11-03 |

## Open-market trades by filing

33 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Avg price | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-03 | 2026-10-30 | Maricel Apuli | Chief Accounting Officer | Sale (10b5-1) | 2,000 | $72.85 | $145.7K | 120,687 | — |
| 2026-09-21 | 2026-09-17 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 10,000 | $69.08 | $690.8K | 495,686 | — |
| 2026-08-20 | 2026-08-18 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 44,980 | $82.86 | $3.7M | Multiple accounts | — |
| 2026-08-03 | 2026-07-30 | Maricel Apuli | Chief Accounting Officer | Sale (10b5-1) | 2,000 | $80.06 | $160.1K | 127,401 | — |
| 2026-07-13 | 2026-07-09 | Jennifer E. Cook | Director | Sale (10b5-1) | 148,589 | $88.54 | $13.2M | 120,805 | — |
| 2026-07-13 | 2026-07-09 | Andrea Ellis | Director | Sale (10b5-1) | 17,167 | $84.00 | $1.4M | 22,579 | — |
| 2026-06-24 | 2026-06-22 | Hannah Valantine | Director | Sale (10b5-1) | 5,004 | $68.25 | $341.5K | 9,259 | — |
| 2026-06-24 | 2026-06-23 | Jennifer E. Cook | Director | Sale (10b5-1) | 39,363 | $69.92 | $2.8M | 8,383 | — |
| 2026-06-17 | 2026-06-15 | Jennifer E. Cook | Director | Sale (10b5-1) | 90,240 | $66.62 | $6.0M | 6,589 | — |
| 2026-06-08 | 2026-06-04 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 80,000 | $67.67 | $5.4M | Multiple accounts | — |
| 2026-05-26 | 2026-05-21 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 26,103 | $69.44 | $1.8M | 267,174 | — |
| 2026-05-19 | 2026-05-15 | Randal W. Scott | Director | Sale (10b5-1) | 10,000 | $67.15 | $671.5K | 11,589 | — |
| 2026-05-19 | 2026-05-18 | Thomas Trimarchi | President and CFO | Sale (10b5-1) | 13,651 | $65.08 | $888.4K | 362,389 | — |
| 2026-05-11 | 2026-05-07 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 80,000 | $67.40 | $5.4M | Multiple accounts | — |
| 2026-05-04 | 2026-04-30 | Maricel Apuli | Chief Accounting Officer | Sale (10b5-1) | 2,000 | $71.58 | $143.2K | 134,115 | — |
| 2026-04-13 | 2026-04-09 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 80,000 | $74.61 | $6.0M | Multiple accounts | — |
| 2026-03-16 | 2026-03-12 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 80,000 | $68.76 | $5.5M | Multiple accounts | — |
| 2026-03-12 | 2026-03-10 | Hannah Valantine | Director | Sale (10b5-1) | 8,671 | $72.00 | $624.3K | 7,465 | — |
| 2026-03-06 | 2026-03-04 | Andrea Ellis | Director | Sale (10b5-1) | 64,921 | $64.87 | $4.2M | 18,589 | — |
| 2026-03-03 | 2026-02-27 | Hannah Valantine | Director | Sale (10b5-1) | 25,484 | $67.41 | $1.7M | 7,465 | — |
| 2026-02-27 | 2026-02-26 | Maricel Apuli | Chief Accounting Officer | Sale (10b5-1) | 2,000 | $66.00 | $132.0K | 121,945 | — |
| 2026-02-23 | 2026-02-19 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 28,053 | $71.39 | $2.0M | 235,053 | — |
| 2026-02-18 | 2026-02-17 | Randal W. Scott | Director | Sale (10b5-1) | 10,000 | $75.46 | $754.6K | 11,589 | — |
| 2026-02-18 | 2026-02-17 | Thomas Trimarchi | President and CFO | Sale (10b5-1) | 13,600 | $74.72 | $1.0M | 336,785 | — |
| 2026-02-18 | 2026-02-17 | Maricel Apuli | Chief Accounting Officer | Sale (10b5-1) | 510 | $74.31 | $37.9K | 123,945 | — |
| 2026-02-12 | 2026-02-10 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 80,000 | $71.86 | $5.7M | Multiple accounts | — |
| 2026-01-12 | 2026-01-08 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 80,000 | $75.54 | $6.0M | Multiple accounts | — |
| 2025-12-16 | 2025-12-15 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 30,011 | $74.64 | $2.2M | 228,776 | — |
| 2025-12-10 | 2025-12-08 | Maricel Apuli | Chief Accounting Officer | Sale (10b5-1) | 2,000 | $74.26 | $148.5K | 130,297 | — |
| 2025-12-08 | 2025-12-04 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 80,000 | $73.86 | $5.9M | Multiple accounts | — |
| 2025-11-24 | 2025-11-20 | Neil Kumar | Chief Executive Officer | Sale (10b5-1) | 26,156 | $65.84 | $1.7M | 228,776 | — |
| 2025-11-19 | 2025-11-17 | Randal W. Scott | Director | Sale (10b5-1) | 10,000 | $66.65 | $666.5K | 17,788 | — |
| 2025-11-19 | 2025-11-17 | Andrew Lo | Director | Sale | 95,599 | $66.11 | $6.3M | Multiple accounts | — |

## Other insider activity (not market trades)

- Option exercises: 31 records
- Tax withholding: 16 records
- Grants and awards: 14 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has BridgeBio Pharma, Inc.'s CEO sold stock?

Yes. Neil Kumar (CEO) sold 725,303 shares ($52.2M) between Nov 2025 and Sep 2026, all under a pre-arranged 10b5-1 plan.

### How current is BBIO’s insider data?

These are BBIO Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The BBIO Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=BBIO&filing_date.gte=2025-11-19&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [BridgeBio Pharma, Inc. (BBIO) stock price](https://massive.com/quote/bbio.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
